BCX9930 – Patient Worthy

source: pixabay.com

BCX9930 Shows Promising Results for Patients with Previously Untreated PNH

Post author:Jessica Lynn
Post published:October 8, 2020
Post category:paroxysmal nocturnal hemoglobinuria

On September 30, 2020, BioCryst Pharmaceuticals ("BioCryst") announced promising data on their drug candidate BCX9930. The therapy, an orally administered Factor D inhibitor, is designed to treat patients with previously…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More